Concepedia
Statistics
Publications
77
Citations
11.2K
H-Index
41
Active since
1999
Affiliations
Istituto Cantonale di Patologia(Current)
Fondazione IRCCS Istituto Nazionale dei Tumori
IFOM
Ospedale San Giovanni Bellinzona
Candiolo Cancer Institute
Milo Frattini is an author at Istituto Cantonale di Patologia specializing in medicine, pathology, and cancer research.
Top concepts
MedicinePathologyOncologyCancer ResearchTumor BiologyRadiation OncologyCell BiologyCancer GeneticsColorectal CancerMolecular Oncology
Publications per year
1999–2022
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations
Retrospective Consortium Analysis, Medicine, Pathology +5
Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text
Kras Mutations, Gastrointestinal Oncology, Medicine +13
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio et al. · JAMA · 2010 · 743 citations
<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore‐Bianchi, Miriam Martini, Francesca Molinari et al. · Cancer Research · 2009 · 735 citations
Side Kras, Pathology, Tumor Biology +17
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
Milo Frattini, Piercarlo Saletti, Elena Romagnani et al. · British Journal of Cancer · 2007 · 536 citations · Full text
1–5 of 77